FN2 Earnings Intelligence
Eli Lilly and Company earnings overview
Latest Eli Lilly and Company (LLY) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Eli Lilly and Company
The Q2 evidence supports a constructive one-year growth case for Lilly: obesity-product momentum, higher guidance, international expansion and pipeline progress outweighed the identified pricing, competition and regulatory risks in this quarter.
Eli Lilly and Company
Q1 2026 marks a pivotal quarter for Eli Lilly. The FDA approval and commercial launch of Foundayo, the first oral GLP-1 therapy for obesity, adds a major new growth engine alongside continued Mounjaro and Zepbound dominance. Revenue grew 56% YoY to $19.8B, exceeding consensus by over $2B, while EPS of $8.55 surpassed estimates by 23%. Management raised full-year guidance to $82-$85B in revenue and $35.50-$37 in non-GAAP EPS, reflecting confidence that volume expansion can absorb U.S. pricing pressure. A session move of nearly 10% and subsequent drift of 18% suggest investors are pricing in sustained incretin franchise leadership. Execution on Foundayo scaling, manufacturing capacity buildout, and access program effectiveness will determine whether that trajectory holds.
Eli Lilly and Company
The supplied analysis supports the view that strong incretin demand and earnings growth can support Lilly's trajectory over the next year. The key test is whether volume growth and new launches offset pricing pressure, reimbursement constraints, competition, and execution risk.
Eli Lilly and Company
The quarter supports the view that earnings growth and resilient demand can underpin the business over the next year: revenue growth accelerated, Mounjaro and Zepbound demand remained strong, and management raised full-year guidance. The thesis still depends on successful orforglipron execution, international reimbursement, pricing discipline, and continued pipeline progress.
Eli Lilly and Company
The supplied analysis supports a constructive operating thesis: strong incretin demand, raised guidance, expanding manufacturing capacity, and pipeline progress may support continued growth. The main tests are pricing and payer pressure, competition, regulatory execution, and supply expansion.
Eli Lilly and Company
The supplied analysis supports a constructive growth thesis for Lilly: incretin demand, new indications, international expansion, and manufacturing investment are intended to sustain growth. The thesis remains conditional on payer access, pricing, supply, pipeline execution, and competition.
Eli Lilly and Company
The quarter supports the view that resilient demand and earnings growth can extend when product adoption, expanded access, and manufacturing capacity advance together. The key test is whether Lilly can convert obesity-therapy demand into durable growth while managing pricing, supply, reimbursement, competition, and investment costs.
Get the LLY recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.